New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
09:04 EDTBCLIBrainStorm Cell receives notice from EPO to grant patent
BrainStorm Cell Therapeutics announced that it has received notification from the European Patent Office of its intention to grant the company’s patent application No. EP06766101.7. This patent relates to the method of production of the company's proprietary stem cells induced to secrete large quantities of neurotrophic factors for the treatment of neurodegenerative diseases. The company's proprietary NurOwn stem cell therapy was developed from this differentiation method.
News For BCLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
09:22 EDTBCLIOn The Fly: Pre-market Movers
Subscribe for More Information
06:58 EDTBCLIBrainStorm NurOwn demonstrates statistically significant effects in ALS patients
BrainStorm Cell Therapeutics is presenting results from its phase 2a study of NurOwn in amyotrophic lateral sclerosis, or ALS, at a poster session today at the American Academy of Neurology annual meeting, taking place in Washington D.C. In addition to previously disclosed topline results, further data and analyses are being presented for the first time. Among the new results is a piecewise linear regression analysis of all subjects who received intrathecal, or IT, administration in the phase 2a study and the prior phase 1/2 study. At six months post-treatment, there was a statistically significant improvement in the estimated rate of decline in Forced Vital Capacity, or FVC, from -5.1% per month pre-treatment to -1.2% per month post-treatment and a nearly significant improvement in the rate of ALS Functional Rating Score-Revised, or ALSFRS-R, decline, from -1.2 points per month pre-treatment to -0.6 points per month post treatment. Also being reported for the first time are local positive effects of intramuscular administration. 3D volumetric analysis using MRI revealed an improvement in the rate of decline in muscle mass in the right arm, the site of NurOwn administration, through one month post-treatment, as compared to the left arm. Electromyography demonstrated a trend of stabilization of the compound motor axon potential in the right musculocutaneous nerve as compared to deterioration observed in the left.
April 14, 2015
09:13 EDTBCLIOn The Fly: Pre-market Movers.
UP AFTER EARNINGS: JPMorgan Chase (JPM), up 1%... Johnson & Johnson (JNJ), up marginally... Triangle Petroleum (TPLM), up 4.2%... Fastenal (FAST), up 5%. ALSO HIGHER: Brainstorm Cell Therapeutics (BCLI), up 13.5% after announcing that it will present NurOwn Phase 2a clinical data at the Academy of Neurology annual meeting... Builders FirstSource (BLDR), up 7.2% after being upgraded to Buy from Hold at Stifel... Solazyme (SZYM), up 7.5% after announcing a strategic agreement with Flotek (FTK)... Cleveland BioLabs (CBLI), up 6.8% after receiving funding recommendation from the Department of Defense... Nordic American Tanker (NAT), up 3.2% after raising quarterly dividend to 38c from 22c... Ocwen (OCN), up 3.8% after reporting preliminary fiscal 2014 results. DOWN AFTER EARNINGS: Wells Fargo (WFC), down just under 1%. ALSO LOWER: Norfolk Southern (NSC), down 5.8% after being downgraded to Hold from Buy at TD Securities... RXi Pharmaceuticals (RXII), down 14.3% after filing to sell $20M of common stock and warrants... Arrowhead Research (ARWR), down 4.5% after being downgraded to Hold from Buy at Jefferies.
08:46 EDTBCLIBrainStorm to present NurOwn Phase 2a clinical data at neurology meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use